Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Lir Life Sciences Corp.
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
May 22, 2026
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
April 28, 2026
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 20, 2026
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
February 6, 2026
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
January 30, 2026
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
January 22, 2026
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
January 15, 2026
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
January 9, 2026
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
December 21, 2025
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
December 13, 2025
1
2
Next Page
→